Digital health and pharmacy group MedPal AI plc (AIM: MPAL) (FRA: Z1N) announced on Monday that it has acquired Solid State Technologies Ltd, trading as eMARx, a provider of electronic medication administration record software for UK care homes and pharmacies, completing its Health OS platform for the care home sector.
eMARx adds a digital medication administration system that enables barcode-verified, real-time recording of medicines, alongside recurring software revenues. For the year ended 31 March 2026, the business generated unaudited revenue of GBP739,231 and profit after tax of GBP106,273.
MedPal said the acquisition strengthens its integrated offering by combining robotic pharmacy dispensing, care home pharmacy supply, private healthcare services, AI-powered patient support and medication administration software. The company believes the platform will support a wider national rollout from its robotic dispensing hub in Runcorn.
Initial consideration is valued at approximately GBP380,000, comprising GBP133,066 in cash and 7,272,834 new ordinary shares, with a completion accounts adjustment expected to increase the total consideration to about GBP474,000. Admission of the consideration shares to AIM is expected on or around 23 July 2026.
Abbott declares quarterly dividend of USD0.63 per share
Gilead Sciences mobilises remdesivir donation to support Ebola response in Uganda
INOVIO's oartner ApolloBio reports positive topline results from Phase 3 trial of VGX-3100
CVS Health announces quarterly dividend of USD0.665 per share
Convatec launches co-branded eakin freeseal ostomy seal in North America
UHS to acquire Talkspace for USD835m
Abbott announces quarterly dividend
Aptamer Optimer technology integrated into Twist Bioscience TrueAmp Library Preparation Kit
Alvotech reports positive PK study results for AVT80 biosimilar candidate
Inspiration Healthcare secures US purchasing agreement to drive Airon growth
West to sell SmartDose 3.5mL On-Body Delivery System rights to AbbVie for USD112.5m
Citius Pharmaceuticals reports full-year financial results
Sanofi receives FDA complete response letter for tolebrutinib in progressive MS